GPCM
AUPH icon

Granite Point Capital Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Granite Point Capital Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-100,000
Closed -$1.3M – 141
2021
Q2 		$1.3M Buy
+100,000
New +$1.27M 0.05% 105
2020
Q1 		– Sell
-100,000
Closed -$2.03M – 76
2019
Q4 		$2.03M Buy
+100,000
New +$921K 0.32% 40

Other funds holding AUPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $8.11B AUM 24.74% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Granite Point Capital Management's AUPH Position: Q3 2021 in Review

Granite Point Capital Management sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2021, closing a stake of 100,000 shares — an estimated $1.3M sold.

Granite Point Capital Management first reported a position in AUPH in Q4 2019 and held it in 2 quarters. The position peaked at $2.03M in Q4 2019. 166 funds tracked by Wall St. Rank hold AUPH as of Q3 2021.

  • Granite Point Capital Management reported no remaining Aurinia Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Granite Point Capital Management sold 100,000 Aurinia Pharmaceuticals shares in Q3 2021, an estimated $1.3M.
  • Granite Point Capital Management first reported a position in Aurinia Pharmaceuticals in Q4 2019 and held it in 2 quarters.
  • Granite Point Capital Management's Aurinia Pharmaceuticals position peaked at $2.03M in Q4 2019.
  • 166 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2021.

Based on Granite Point Capital Management's 13F filing for Q3 2021, filed 10 Nov 2021.